TY - JOUR
T1 - Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery
AU - Zummo, Giovanni
AU - Bucchieri, Fabio
AU - Sciume', Carmelo
AU - Campanella, Claudia
AU - Pitruzzella, Alessandro
AU - Curcuru', Giuseppe
AU - Marino Gammazza, Antonella
AU - Farina, Felicia
AU - Caruso Bavisotto, Celeste
AU - Cappello, Francesco
AU - Modica, Giuseppe
AU - David, Sabrina
AU - Barone, Rosario
AU - Rappa, Francesca
AU - Geraci, Girolamo
AU - Campanella, Claudia
AU - Marino Gammazza, Antonella
AU - Pitruzzella, Alessandro
AU - Barone, Rosario
AU - Rappa, Francesca
AU - Caruso Bavisotto, Celeste
AU - Curcurù, Giuseppe
AU - Bucchieri, Fabio
AU - Fais, Stefano
AU - Cappello, Francesco
AU - Conway De Macario, Everly
AU - Macario, Alberto J.L.
PY - 2015
Y1 - 2015
N2 - BACKGROUND: Heat shock protein 60 (Hsp60) is a chaperonin involved in tumorigenesis, but its participation in tumor development and progression is not well understood and its value as a tumor biomarker has not been fully elucidated. In the current study, the authors presented evidence supporting the theory that Hsp60 has potential as a biomarker as well as a therapeutic target in patients with large bowel cancer. METHODS: The authors studied a population of 97 subjects, including patients and controls. Immunomorphology, Western blot analysis, and quantitative real-time polymerase chain reaction were performed on tissue specimens. Exosomes were isolated from blood and characterized by electron microscopy, biochemical tests, and Western blot analysis. RESULTS: Hsp60 was found to be increased in cancerous tissue, in which it was localized in the tumor cell plasma membrane, and in the interstitium associated with cells of the immune system, in which it was associated with exosomes liberated by tumor cells and, as such, circulated in the blood. An interesting finding was that these parameters returned to normal shortly after tumor removal. CONCLUSIONS: The data from the current study suggested that Hsp60 is a good candidate for theranostics applied to patients with large bowel carcinoma and encourage similar research among patients with other tumors in which Hsp60 has been implicated.
AB - BACKGROUND: Heat shock protein 60 (Hsp60) is a chaperonin involved in tumorigenesis, but its participation in tumor development and progression is not well understood and its value as a tumor biomarker has not been fully elucidated. In the current study, the authors presented evidence supporting the theory that Hsp60 has potential as a biomarker as well as a therapeutic target in patients with large bowel cancer. METHODS: The authors studied a population of 97 subjects, including patients and controls. Immunomorphology, Western blot analysis, and quantitative real-time polymerase chain reaction were performed on tissue specimens. Exosomes were isolated from blood and characterized by electron microscopy, biochemical tests, and Western blot analysis. RESULTS: Hsp60 was found to be increased in cancerous tissue, in which it was localized in the tumor cell plasma membrane, and in the interstitium associated with cells of the immune system, in which it was associated with exosomes liberated by tumor cells and, as such, circulated in the blood. An interesting finding was that these parameters returned to normal shortly after tumor removal. CONCLUSIONS: The data from the current study suggested that Hsp60 is a good candidate for theranostics applied to patients with large bowel carcinoma and encourage similar research among patients with other tumors in which Hsp60 has been implicated.
UR - http://hdl.handle.net/10447/145501
M3 - Article
VL - 121
SP - 3230
EP - 3239
JO - Cancer
JF - Cancer
SN - 0008-543X
ER -